Helicobacter pylori Interactions with Host Serum and Extracellular Matrix Proteins: Potential Role in the Infectious Process

J. Daniel Dubreuil,* Giuseppe Del Giudice, and Rino Rappuoli

IRIS Research Center, Chiron SpA, 53100 Siena, Italy

INTRODUCTION

Helicobacter pylori is a gram-negative spiral-shaped bacillus that colonizes the gastric mucosa of humans (57). This bacterium is microaerophilic and neutralophilic and is capable of neutralizing the acidic environment owing to the production of a urease (about 6% of the cellular protein content) that is released by cell lysis (53). The production of catalase is also important because catalase-negative mutants survive poorly (71). This bacteria is extremely motile, even in viscous environments like the gastric mucus, by virtue of one to six polar sheathed flagella (73). When exposed to a hostile environment or other high-stress conditions, the bacterium transforms from its spiral highly motile form to a coccoid form (39). *H. pylori* was first cultured in vitro and shown to be associated with gastritis and peptic ulcers by Marshall (54) and Warren (109). Once established in the host stomach, it remains in the mucosal environment virtually for the host's entire life (25). Infection with *H. pylori* remains one of the most common bacterial infections worldwide (29, 70), affecting over 50% of humans (91). The prevalence of *H. pylori* infection reaches 90% or more in developing countries (96). The vast majority of infections persist for life with the same colonizing strain unless an eradication attempt is successful (62). Oral-to-oral, fecal-to-oral, and gastric-to-oral transmission account for most infections (29, 70).

The majority of infections are acquired early in life, probably in childhood from close contact with parents (most probably from the mother) or other children (23, 52, 85, 97). In fact, the major risk factors for acquisition of this long-lasting infection in all countries are childhood and low socioeconomic status. The observed differences in the prevalence of the infection are probably related to hygiene conditions and sanitation (70).

H. pylori infection is associated with chronic gastritis, peptic ulcers, atrophic gastritis, intestinal metaplasia, gastric adenomas, gastric hyperplastic polyps, adenocarcinomas of the distal part of the stomach, and lymphomas of mucosa-associated lymphoid tissue (29, 33, 46, 61, 70, 74, 91). These diseases, in most instances, develop many years after the host colonization.

The sequences of the entire genomes of two unrelated pathogenic strains of *H. pylori* (J99 and 26695) have been reported (1, 98). This work demonstrated that even though the chromosomes are organized differently in a limited number of discrete regions, the genome size, genetic content, and gene order of the two strains examined are surprisingly conserved (35).

To date, numerous virulence factors responsible for gastric colonization, survival, and tissue damage have been described and characterized for *H. pylori* (for a review, see reference 65) (Table 1). The critical feature of *H. pylori* may, however, reside not in its ability to damage host tissues but rather in its special ability to persist within the host for such a long period. Many of the pathogenic events seen during *H. pylori* infection may be due to the alteration of the host response by the bacterium. This explains why *H. pylori* flourishes in the human stomach despite an important local immune response and can restore colonization with only few bacteria surviving after failure of therapeutic eradication. Underscoring the virulence of microbial pathogens is their capacity for adaptation and survival in variable and often hostile environments encountered in the host.

H. pylori infection is associated with a marked infiltration of the gastric epithelium by neutrophils, macrophages, lympho-

* Corresponding author. Permanent address: Université de Montréal, Faculté de Médecine Vétérinaire, Dép. pathologie et microbiologie, 3200 Sicotte, St-Hyacinthe, Québec, Canada, J2S 7C6. Phone: (450) 773-8521 ext. 8433. Fax: (450) 778-8108. E-mail: daniel.dubreuil @umontreal.ca.

TABLE 1. Virulence factors of *H. pylori*[a]

Factor	Function	Distribution	Reference
Urease	Buffering of stomach acidity	All strains	38
NixA	Nickel uptake for urease	All strains	63
Flagella	Motility	All strains	40
Superoxide dismutase	Resistance to killing by phagocytes	All strains	93
Catalase	Resistance to killing by phagocytes	All strains	71
NAP	Neutrophil activation	All strains	27
BabA	Adhesin for Lewis b antigen	Type I strains	10
VacA	Cytotoxicity	Most strains	20
CagA	Immunodominant antigen	Type I strains	19
PAI	Genes (31) encoding type IV secretion system	Type I strains	13
Lewis X and Y	Molecular mimicry	Many strains	4

[a] Adapted from references 64 and 65.

cytes, and plasma cells. Despite the presence of phagocytes in close vicinity to the bacteria, a significant number of infected people are unable to eradicate the microbe, since the fate of *H. pylori* that comes into contact with phagocytes also depends on which molecules are bound to its cell surface. Interaction with fetuin, heparan sulfate, vitronectin, and hyaluronic acid, for example, in the presence of complement was shown to inhibit phagocytosis by macrophages (14).

In this review, we focus on the interaction (specific and less specific) of cell surface molecules of *H. pylori* with soluble serum proteins and extracellular matrix (ECM) proteins, of which many are also present in host serum, of the human host with which the bacterium comes into contact once the tissues have been damaged through the action of toxic factors.

We know that *H. pylori* binds host proteins (immunoglobulin, albumin, heparin, etc.) and that some of these interactions are of high affinity: they could thus play an important role in the infectious process. Microbial proteins with binding properties for mammalian proteins are now called receptins (41), and this term is used throughout this review. This term excludes the first step of adherence to the mammalian cell surface required for a microorganism to establish itself in a host; rather, it refers to the later stages that permit the persistence of a long-lasting infectious process through binding to soluble host cell proteins. Thus, this interplay of binding of *H. pylori* with host proteins represents a way to adapt to an evolving infection and to evade the host immunological response, which would normally tend to establish protective immunity. This review summarizes current knowledge of *H. pylori* binding to serum and ECM proteins and on the biological significance of these interactions during the infectious process.

RATIONALE FOR BACTERIAL ADHESINS AND RECEPTINS

To be infectious, pathogenic bacteria have to adhere to tissues they encounter in order to overcome removal by the natural (physical) mechanisms in place to get rid of invaders. Adherence is the first step of the pathogenic process that permits colonization by the microorganism. The persistence of the bacterium and growth in a particular niche within the host can occur without the production of any detrimental effect on the host. Adhesins are bacterial proteins, glycoconjugates, or lipids involved in the initial stages of colonization mediating the interaction between the bacterium and the host cell sur-

face. Adherence of bacteria to host cell receptors (composed of lipids, proteins, glycolipids or glycoproteins) triggers cellular changes that include signal transduction cascades, leading to infiltration of inflammatory cells (neutrophils and monocytes) and eventually to persistence of the microorganism (95). A receptin, however, does not necessarily induce a secondary effect (41). It has become evident over the past decade that many microorganisms express cell surface receptins mediating microbial adherence to host tissues. These ligand interactions are important steps in the molecular pathogenesis of many infections (76, 110). Bacteria use, as well as nonspecific hydrophobic and electrostatic forces, surface proteins with specific affinity for plasma proteins and for components of the ECM. In addition to being surface exposed, some of these proteins are also released by the bacterium. In a healthy, normal human the ECM is not exposed and thus is not accessible for interaction with bacteria. However, these molecules could become exposed after a tissue trauma following a mechanical or chemical injury or after an infection.

H. pylori has evolved adherence and colonization mechanisms to maintain itself specifically in the gastric mucosa. It is highly adaptable, as evidenced by the fact that it can infect a host for decades. It can physically interact with host cells and mucins via a number of different adhesins displaying a variety of unique receptor specificities (for a review, see reference 95). The adherence to gastric epithelial cells is readily demonstrated in tissue culture and in gastric biopsy specimens. It is noteworthy that *H. pylori* possesses a fibrillar hemagglutinin that binds to *N*-acetylneuraminyl-(alpha-2-3)-lactose (95). This property permits us to divide *H. pylori* strains into hemagglutinating and non-hemagglutinating strains (28).

The bacteria following an oral infection probably reach the stomach covered with salivary mucins containing both sialylated and sulfated components that are known to bind to *H. pylori* (60). After ingestion, *H. pylori* colonizes the human gastric mucus and epithelium by several specific adhesins (95). No cell invasin has been identified for *H. pylori,* and most researchers agree that cell invasion is a rare event (9, 12), although a very recent in vitro study suggested that *H. pylori* is able to invade cultured gastric epithelial cells via a zipper-like mechanism (43). This microorganism seems, rather, to gain access to the submucosal layer by passing through the intercellular tight junctions (107). The process is probably facilitated by expression of binding molecules for host serum and ECM proteins

after gastric cell lesions are induced by ammonia as a result of urease activity and *H. pylori* toxins (107). It is likely that *H. pylori* uses binding to one or more of these ECM and/or serum proteins to penetrate the intercellular junctions of gastric epithelial cells. These adherence-penetration phenomena also involve coating with host proteins to escape the immune system and initiate a chronic lifelong infection (107). In addition, *H. pylori* cells coat themselves with host molecules to prevent attacks by professional phagocytes and strong immune reactions and to promote colonization and survival in the host. Thus, microbial receptins as such represent an attractive target for the development of new antimicrobial therapeutics.

INTERPLAY OF *H. PYLORI* VIRULENCE FACTORS RESULTING IN CELL DAMAGE

Urease, cytotoxin-associated gene A (CagA), vacuolating cytotoxin A (VacA), and neutrophil-activating protein (NAP) are important determinants of *H. pylori* stomach colonization and pathogenicity (65). They also represent major antigens implicated in the human response to *H. pylori* infection; some are being used as components of vaccine preparations (22).

Briefly, from what we know now of the pathogenesis of this microorganism, *H. pylori* enters the gastric lumen and, through its urease activity, survives in this highly acidic, hostile environment. Ammonia molecules are produced that buffer the acidic pH (38). Because of the helical shape, the bacterium is efficiently propelled through the mucus layer, covering the gastric epithelium, via polar sheated flagella (72, 73). Reaching the apex of the gastric epithelial cells, it sticks to them through specialized adhesins (95). CagA protein is then injected into the host cells by using a type IV secretion system (18). CagA is part of a pathogenicity island (PAI) and is associated with type I strains, which are responsible for severe forms of gastroduodenal disease (13). Other toxic factors are released as well, including NAP and VacA. VacA induces alterations of the tight junctions and formation of vacuoles (20, 21); it was recently shown to promote urea diffusion across the epithelia, possibly favoring *H. pylori* infectivity in vivo by optimizing urease activity (99). NAP crosses the epithelial lining and recruits neutrophils, monocytes, and mast cells, causing tissue damage through the release of oxygen radicals and other factors (67, 88). Injection of CagA causes cell cytoskeleton alteration and pedestal formation and signals the nucleus to release proinflammatory lymphokines. Taken together, the direct toxic activities of VacA and of the oxygen radicals and the proinflammatory activity and indirect activities mediated by other bacterial molecules lead to tissue damage that is enhanced by loosening of the protective mucus layer and acid permeation.

The interplay of *H. pylori* virulence factors leads to host tissue damage that exposes the ECM proteins as well as serum proteins with which the bacterium can now come into contact. *H. pylori* causes chronic infection during which several mechanisms lead to damage of the epithelial cell integrity. At different stages of the infection process, it is expected that the bacterium interacts with serum and ECM proteins which would otherwise be "hidden" from the pathogen. These additional interactions would be responsible for an even more complex dynamic between the bacterium and the host, causing a lifelong persistence of the infection.

SERUM PROTEINS BINDING TO *H. PYLORI*

Immunoglobulin

Several bacterial species express surface proteins that interact with immunoglobulins (Igs) in a nonimmune fashion [i.e., not through the specific binding site of F(ab′)$_2$]. These molecules provide pathogens with the potential to evade or elude the host defenses by interfering with opsonization, phagocytosis, or complement activation and consumption (111).

Tosi and Czinn (100) reported that binding of IgG to *H. pylori* promoted phagocytosis and killing in vitro by polymorphonuclear leukocytes. *H. pylori* strains are susceptible to complement and activate either the classical pathway, even in the absence of specific antibodies, or the alternative pathway (7, 32). Nevertheless, most patients with chronic active type B gastritis show a high titer of specific antibodies to *H. pylori* yet fail to resolve the infection. Mattsson et al. (56) demonstrated that in *H. pylori* infection, a strong antibody response is generated in the gastric mucosa both in asymptomatic carriers and in patients with duodenal ulcer. No difference in either antigen specificity or magnitude of the B-cell response in the stomach could be detected in these two groups of subjects. Thus, *H. pylori* seems capable of evading host opsonic phagocytosis mechanisms in vivo. Even though those individuals develop a seemingly vigorous humoral response to the infection, they do not eliminate the bacteria. This is why we now think that a vaccination strategy against this pathogen needs to be capable of stimulating cellular immunity (26). Reasons for this observation may be that *H. pylori* either could react in a nonimmune way with Igs, thus affecting the normal opsonization process, or could enzymatically degrade the specific Igs produced in response to the infection.

In a descriptive study, Amini et al. (3), using a particle agglutination assay in which IgG was immobilized on latex beads, indicated that *H. pylori* strains commonly expressed IgG-binding proteins, since 24 of the 32 strains studied had bound human IgG. In a subsequent investigation, the protein that was binding human IgG in a nonimmune way was identified as a 60-kDa cell surface-associated heat shock protein (Hsp) (2). This protein could bind human IgG1, IgG3 and IgM. Binding was inhibited by the kappa chain of human IgG but not by the Fc fragment, suggesting that the interaction occurs through the Fab region of the IgG molecule. No reaction was noted with human IgA, rabbit IgG, or mouse IgG. Thus, the characteristics of the *H. pylori* IgG-binding activity seem to differ from those of *Staphylococcus* and *Streptococcus* species (11).

The uptake of host Igs by bacterial strains expressing IgG-binding proteins may, in theory, interfere with the defense mechanisms. This reaction at the cell surface of the pathogen could influence the coexistence of the host and the parasite and may help the microorganism to evade the host defense by a mechanism of molecular mimicry (37). In addition, Hsp60, identified as the Ig-binding protein in *H. pylori,* represents a family of heat shock proteins that are immunodominant antigens of many microbial pathogens that could induce immune tolerance in the host (80).

Immunization with *H. pylori* heat shock proteins induces protective immunity in a murine model of *Helicobacter felis*

infection (30). Since *H. pylori* Hsp does not bind mouse IgG, in contrast to human IgG, as demonstrated by Amini et al. (2), one could hypothesize that in this animal model, protection is achieved through the specific immune responses and interactions between the Hsp and the specific binding sites of the antibodies induced. In contrast, natural infection of humans with *Helicobacter* is able to establish itself and be maintained as a persistent infection despite the production of antibodies to a number of *H. pylori* proteins, including Hsp (45, 51). This is probably because of the higher propensity of Hsp to bind to Igs in a nonimmune manner.

One other conceivable mechanism to elude the antibody-mediated protection could be due to the direct alteration of the Igs produced by the host in response to the invading pathogen. A study by Berstad et al. (8) of the mucosal production of IgA in response to *H. pylori* gastritis reported that a substantial increase in the number of Ig-producing cells occurred, particularly of the IgA1 isotype. *H. pylori* did not produce IgA1-specific or nonspecific IgA-degrading protease activity, ruling out the hypothesis that *H. pylori* is capable of enzymatically degrading IgA. Nevertheless, a recent study showed that an unidentified cell wall protein of *H. pylori* was reported to bind enzymatically deglycosylated human IgG (55). The IgG of patients infected with *H. pylori* also bound to this protein and consequently lost the reactivity of the sugar chain structure. These observations suggested to the authors that *H. pylori* infection was related to human IgG deglycosylation.

Albumin

Albumin is the most abundant protein in human serum. It interacts reversibly with a wide variety of endogenous (long- and medium-chain fatty acids, bilirubin, and hemin) and exogeneous compounds and serves as an important depot and transport protein (78).

An exploratory investigation using human and bovine serum albumin immobilized on latex beads was conducted. Of the 32 strains of *H. pylori* tested, 16 could interact with bovine serum albumin and 12 could react with human serum albumin (3). This binding was probably due to nonspecific and hydrophobic interactions, since the binding was inhibited by chaotropic agents. In addition, the albumin-binding activity could not be extracted from the bacterial surface by using either glycine buffer or phosphate buffer or by sonication. Nevertheless, the hydrophobic interaction of albumin and *H. pylori* could have implications in the pathogenesis process. In fact, covering *H. pylori* with albumin found in serum could help the microbe to evade the defense mechanisms of the host by a mimicry stratagem. In addition, we cannot exclude the possibility that albumin, as a major transport protein, could, after binding to bacterial surface, provide substances to be used by the bacterium as nutrients in a similar manner to that suggested to occur in group G streptococci (89). It is not yet clear, however, why some *H. pylori* strains bind albumin better than others and whether this is associated with an increased virulence. In vivo experiments should be conducted to answer these intriguing questions.

EXTRACELLULAR MATRIX COMPONENTS

ECM is a biologically active tissue comprising glycoproteins and glycosaminoglycans, which form a network through a number of specific interactions between different ECM components. The composition of ECM differs in various organs, but fibronectin, collagen types I to XV, laminin, and glycosaminoglycans such heparan sulfate, chondroitin sulfate, and others are prevalent molecules (49). The ECM serves a structural function but also affects eukaryotic cell adhesion, differentiation, migration, and proliferation. Laminin, type IV collagen, and heparan sulfate are major constituents of basement membranes. Several ECM components are also found in plasma and other body fluids.

Interaction of microorganisms with ECM could play an important role in the establishment and maintenance of long-lasting deep tissue infection. Whether the infection remains superficial or proceeds into subepithelial tissues depends on the strain characteristics as well as the host immune response. Bacteria come in contact with the ECM after either physical or chemical alterations have occurred and proteolytic enzymes and/or toxins have disrupted the skin or epithelial integrity. The normal shedding of epithelia (18 to 24 h for gastric epithelium) could also expose ECM components. Coating of bacterial cells with some of the molecules exposed could represent a mechanism to evade host immune defense mechanisms, for example.

Expression of receptins for various ECM components is influenced by bacterial culture conditions and may appear at different stages of growth. For example, *H. pylori* expresses ECM-binding molecules during the stationary phase of growth. For specific ECM molecules, it was observed that both coccoidal and spiral forms of the organism express binding to a similar extent (39). When studying the interactions of bacteria with the ECM, it is important to grow the bacteria under in vivo-like conditions since pH, redox potential, divalent cations, and iron availability could represent important factors for their expression (49). A large number of intracellular and extracellular human pathogens adhere to the mammalian ECM and have been shown to contribute to the virulence of the microorganisms (77, 110).

Heparin and Heparan Sulfate

Heparin and heparan sulfate constitute a class of glycosaminoglycans with common structural features. Heparin is a sulfated glycosaminoglycan best known for its anticoagulant activity. It is produced by mast cells and is stored in intracellular granules; it does not represent a normal constituent of the ECM. It is found in various animal tissues, particularly the liver, lungs, and gut. A close structural relative, heparan sulfate, is found in the ECM on the surface of most animal cells. This acidic glycosaminoglycan, a component of cell surface- or basement membrane-associated proteoglycans, is produced by both epithelial and mesenchymal cells. Heparin is more extensively sulfated than is heparan sulfate. Many microorganisms express heparin- or heparan sulfate-binding surface proteins (76). Recent studies indicate that *H. pylori* may actively favor this interaction by enhancing the availability of heparin in the epithelial and subepithelial environment. In fact, NAP is able

to cross the epithelial layer to activate mast cells with consequent degranulation and release of the granule content (67). Recently, VacA has also been shown to recruit and activate mast cells (94).

H. pylori was screened for binding to the ECM components heparan sulfate and heparin (5). Heparan sulfate could bind *H. pylori* strains isolated from patients with gastroduodenal ulcer-related diseases. Of the 20 strains studied, 90% bound ^{125}I-heparan sulfate. Another study using *H. pylori* strain CCUG 17874 and strain 25 indicated high-level binding of ^{125}I-labeled heparin (108). This common property involves a protein receptor-ligand binding interaction. The low binding at high pH (pH 8) and high binding at low pH (pH 4), as well as the binding inhibition at high ionic strength (2 M NaCl), suggested that charge interactions were important for optimal binding. The observations that pepsin treatment of *H. pylori* did not affect the capacity for binding to heparan sulfate and that binding had a low pH optimum (pH 4 to 5) could be significant in the pathogenesis of the gastric infection caused by *H. pylori*. This is because in vivo, the pepsin and acidic pH found in the gastric environment of *H. pylori* may not interfere with binding to heparan sulfate. This interaction was inhibited by various sulfated polysaccharides at high ionic strength and high pH but was not inhibited by carboxylated or nonsulfated compounds (36). The inhibition was related to the sulfate content of the molecule but was not related to the carbohydrate polymer backbone.

Utt and Wadström (103) confirmed that binding of heparan sulfate by *H. pylori* at pH 4 to 6 is very common among *H. pylori* strains. As the previous study had indicated, inhibitory assays with various compounds such as dextran sulfate and carrageenans revealed that inhibition was related to the sulfate content of the molecule, not to the carbohydrate polymer backbone. The calculated 50% inhibitory concentration (IC$_{50}$) was 3.55×10^{-7} M heparin and 5.01×10^{-6} M dextran sulfate, respectively, for *H. pylori* strain 25. The heparin-binding protein is located at the cell surface, as revealed by biotinylation of cell surface proteins and an indirect-immunofluorescence assay; it could correspond to a polypeptide of 55 to 60 kDa.

Proteins with heparan sulfate affinity were recently isolated from *H. pylori* culture supernatants by affinity chromatography on heparin-Sepharose (86). Two major extracellular proteins with heparan sulfate affinity were identified by preparative isoelectrofocusing, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and blotting experiments using peroxidase-labeled heparan sulfate. One protein had a molecular mass of 66.2 kDa and a pI of 5.4, while the other was a 71.5-kDa protein with a pI of 5.0. NH$_2$-terminal amino acid sequencing was performed on those proteins. The 66.2-kDa heparan sulfate-binding molecule showed a high homology to *Escherichia coli* chaperon proteine and equine hemoglobin. A third protein binding heparan sulfate was isolated from an outer membrane protein fraction of *H. pylori* and shown to have a molecular mass of 47.2 kDa.

Utt et al. (102) reported that the C-terminal domain of the 58-kDa subunit of *H. pylori* VacA was also binding to heparin and heparan sufate. Using surface plasmon resonance and synthetic VacA toxin peptides corresponding to predicted binding peptides as inferred by using bioinformatic tools, they showed that heparan sulfate might represent a receptor/core-ceptor for VacA cytotoxin. These findings supported an earlier study indicating that the binding site for the toxin receptor is located in the 58-kDa C-terminal domain (81). Although the observed binding has moderate affinity ($K_a = 4.89 \times 10^5$ M^{-1}), the multimeric form of VacA cytotoxin may bind heparan sulfate through several domains and hence may contribute to a much stronger interaction. Experiments using cells in culture showed that inhibition of cell vacuolation was observed following treatment of *H. pylori* cells with heparin (92), confirming the surface plasmon resonance study.

As a pathogenic mechanism, *H. pylori* could also interfere with growth factors and growth factor receptors important for the gastroduodenal mucosa integrity. In fact, Ascencio et al. (6) demonstrated that *H. pylori* not only binds to heparin-binding fibroblast growth factors (FGFs) with an extremely strong affinity ($K_d = 3.8 \times 10^{-12}$ M), but also could bind to heparan sulfate and heparin with higher affinity (9×10^{-9} M) (Table 2) than FGFs bind to heparin (10^{-8} to 10^{-9} M) (Fig. 1). *H. pylori* binds two heparin-binding growth factors (i.e., acidic and basic FGFs). Heparan sulfate-binding proteins are exposed on the surface of the microbe as well as it is shed from the surface; they are often localized close to epithelial stem cells in the gastroduodenal glands (5). Since FGFs are dependent on heparin for activation, *H. pylori* could efficiently interfere with growth factors and growth factor receptors, resulting in disturbances of the balance controlling the renewal, maintenance, and repair of the gastroduodenal mucosa, which are commonly observed during *H. pylori* infections. The high binding affinity to heparin and heparan sulfate of *H. pylori* could reduce the availability of FGF and result in its injurious effect on the human mucosa by inhibitory or repressive effects on the renewal and differentiation of gastroduodenal epithelial cells as well as the restoration of the tissue after damage. Heparin-binding proteins could play a role in the development of peptic ulcers by interfering with the availability and bioactivity of heparin-binding growth factors as well as of heparan sulfate.

Recently, heparan sulfate-binding proteins were shown to be involved in the adherence of *H. pylori* cells to HeLa S3 and Kato III cells (34). A 71.5-kDa extracellular heparan sulfate-binding protein was involved in promoting attachment to those cells, and rabbit polyclonal antibodies against this molecule could inhibit the adherence of *H. pylori*.

Despite recruitment of numerous phagocytes to the inflammatory foci in the gastric mucosa, infected people are unable to eliminate the bacteria. It has been established that strains expressing heparan sulfate-binding proteins interact with phagocytes via those molecules (15, 17). Human and murine neutrophils and macrophages seem to recognize mainly the hemagglutinins on the surface of *H. pylori* strains and also heparan sulfate-binding proteins on other strains (16). Treatment of *H. pylori* with heparin caused a dramatic decrease in phagocytosis, probably due to a decrease of the surface hydrophobicity (14). Preincubation of the bacteria with heparin inhibited the ingestion process by 55 to 70%. Deposition of sialic acid-containing compounds, heparin, and vitronectin in the presence of complement on the bacterial surface rendered the bacteria resistant to phagocytosis (14). It is probable that in an inflamed tissue, binding of these compounds by *H. pylori* allows the bacteria to avoid phagocytosis.

Duensing et al. (24) describe a novel, extragenomic mecha-

TABLE 2. Host serum and ECM proteins shown to bind *H. pylori* cells in vitro, the receptins involved, and the affinity of the interaction

Serum and ECM proteins	Receptin(s)	Affinity $(K_d)^a$	References[c]
Albumin	Not identified	ND^b	Amini et al. (3)
Human IgG1, IgG3, and IgM	60-kDa Hsp	ND	Amini et al. (3) Amini et al. (2)
Collagen (Type IV)	Not identified	1.6×10^{-10} M	**Trust et al. (101)** Khin et al. (39) Ringnér et al. (82)
Fibronectin and fibrinogen	Not identified	ND	Trust et al. (101)
Heparin and heparan sulfate	47.02-, 66.2- and 71.5-kDa proteins and the 58-kDa subunit of VacA cytotoxin	9×10^{-9} M	**Ascencio et al. (5)** Ruiz-Bustos et al. (86) Utt et al. (102) Wadström et al. (108) Ljungh et al. (48) Slomiany et al. (90)
Laminin	LPS and/or 25- and 67-kDa proteins	7.9×10^{-9} M 8.5×10^{-12} M 2.5×10^{-9} M	**Trust et al. (101)** **Valkonen et al. (104)** **Valkonen et al. (105)** Valkonen et al. (106) Khin et al. (39)
Plasminogen and plasmin	42-, 57-, and 58.9-kDa proteins	7×10^{-7} M	**Ljungh (47)** Pantzar et al. (75) Ringnér et al. (83) Ringnér et al. (82)
Vitronectin	Not identified	ND	Trust et al. (101)

[a] The affinity of the serum and ECM proteins toward *H. pylori* cells.
[b] ND, not determined.
[c] References in bold are those from which the affinity dissociation constants were taken.

nism of bacterial surface modulation that could amplify the adaptive and pathogenic potential of numerous bacterial species, including *H. pylori*. The mechanism described involved specific bacterial recruitment of molecules found in the immediate environment during the infection process, such as heparin, glycosaminoglycans, and related sulfated polysaccharides. These molecules could then serve as universal binding sites for a diverse array of mammalian heparin-binding proteins. The recruited molecules could bind to adhesive glycoproteins (vitronectin and fibronectin), inflammatory (monocyte chemotactic protein 3, platelet factor 4, and macrophage inflammatory protein 1α), and immunomodulatory (gamma interferon) factors, and FGF. A study by Ascencio et al. (6) had clearly shown that preincubation of *H. pylori* cells with heparan sulfate and other sulfated polysaccharides resulted in enhanced FGF binding, supporting the novel microbial pathogenesis strategy proposed by Duensing et al. (24). This strategy may have a major impact on key aspects of microbial pathogenicity, as revealed


FIG. 1. Comparison of the dissociation constant between *H. pylori,* acidic FGF (aFGF), and heparan sulfate or heparin. Adapted from reference 6.

by the observed increase in bacterial invasion of epithelial cells and inhibition of chemokine-induced chemotaxis (24).

Fibronectin and Fibrinogen

Fibronectin is a 440-kDa glycoprotein found in the ECM and body fluids of animals. It was the first ECM protein shown to act as a substrate for adherence of microorganisms to eukaryotic cells (42). Fibrinogen is a 340-kDa glycoprotein that is found in high concentrations in plasma, where it plays important roles in blood coagulation and wound-healing processes. It forms the structure of the blood clot and becomes deposited in the wound matrix primarily as a consequence of its proteolytic conversion to fibrin. Fibrin or fibrinogen could serve as a substrate for microbial receptins. Although fibrinogen has been shown for *S. aureus* to be an important molecule to which the bacteria bind (31), for *H. pylori* only a low level of binding was observed (between 5 and 7%) (83). Fibronectin also binds weakly (3 to 23%) to *H. pylori* (39, 101).

Collagen

A key feature of certain successful gram-positive and gram-negative bacteria is the ability after binding to cutaneous or mucosal surfaces to invade deep tissues. Collagen proteins are the major constituents of the ECM and as such may represent a major target site for microorganisms. Following attachment of *H. pylori* to the gastric epithelial cells, as discussed above, toxicity is exhibited. In certain cases, this leads to the destruction of the cells, loss of tissue integrity, and ultimately complete erosion of the epithelium, leaving the underlying basement membrane completely bare. Thus, in ulcerated tissue, the various connective tissue proteins, including those of the basement membrane, become exposed and available to colonizing bacteria. Therefore, the capacity to bind to such matrix proteins may be extremely important for *H. pylori* to colonize and damage the basement membrane before invading the lamina propria in the process of eliciting ulcerative lesions.

Collagen is a major protein of the ECM. Type IV collagen forms a two-dimensional reticulum and is a major component of the basal lamina. Type IV collagen binds at high levels to *H. pylori* (average binding, 27%; highest binding, 60%), while the bacterium is also capable of binding low levels of type I and II collagens (101). The ability of 16 isolates of *H. pylori* to bind ^{125}I-collagen was quantitated using a liquid-phase assay. Results showed that binding is rapid, not affected by pH, and saturable, indicating a limited number of receptors. The number of available binding sites on the bacterial surface was calculated to be approximately 3,000. Once bound, radiolabeled type IV collagen was not displaced by an excess of unlabeled molecule, indicating that the interaction was of high affinity (K_d = 16 nM). The ability to specifically bind to this component of the basement membrane is likely to represent an important virulence property for this gastric pathogen. The molecule(s) responsible for the interaction with collagen has not been identified yet.

Laminin

Laminin is one of the major glycoproteins of basement membranes (with type IV collagen) that plays a role in cellular adhesion processes. It anchors the cell surface to the basal lamina. It is a complex noncollagenous glycoprotein, which is important for the structure of the basement membrane by formation of networks with type IV collagen, entactin/nidogen, and heparan sulfate proteoglycans. It is involved in cell adhesion to basement membranes by normal cells, metastiting tumor cells, and some pathogenic bacteria (104). A characteristic feature of laminin is its high carbohydrate content (12 to 27%), most of which is present in complex-type oligosaccharides. Hence, it is not surprising that *H. pylori* as well as other microbes bind to this molecule by lectin interactions (48). The capacity of *H. pylori* strains to bind to laminin is unlikely to be involved in the initial colonization of gastric mucosal cells, since specific primary adherence is done through receptors in the mucus layer and on the epithelial cell surface (95). Nevertheless, this property would assume major importance once the basement membrane becomes exposed. The bacteria appear to undermine the mucosal integrity by penetrating the tight junctions of epithelial cells (107). Laminin binds *H. pylori* via surface proteins (104) and lipopolysaccharide (LPS) (105).

In a study by Valkonen et al. (104), *N*-acetylneuraminyllactose decreased laminin binding by 70% and neuraminidase treatment of laminin decrease binding by 50%, while a recombinant B_1 chain of laminin, containing high-mannose-type oligosaccharides, inhibited binding by only 25%, suggesting that terminal sialic acids on laminin were competing for a specific sugar-binding protein on *H. pylori* cells. The receptor involved in this binding appeared to be proteinaceous since it was heat and protease sensitive. Scatchard analysis of specific binding indicated that approximately 2,000 sites per cell were present (104). The interaction of *H. pylori* with laminin involves a bacterial receptin recognizing certain sialylated oligosaccharides of the glycoprotein (105). Since the carbohydrate moiety of laminin is thought to play a role in eukaryotic cellular adhesion processes such an interaction of *H. pylori* with laminin could further disorganize the gastric epithelium. Trust et al. (101) showed that the interaction of *H. pylori* with laminin was rapid (15 to 30 min), of high affinity (K_d = 7.9 nM), and partially reversible. Since the binding was affected by salt, it suggested the presence of a hydrophobic component in this interaction (101).

Valkonen et al. (105) indicated that although all *H. pylori* strains tested bound laminin, hemagglutinating strains were good binders of laminin (maximum, 31%) compared to nonhemagglutinating strains (minimum, 6%). In their study, *H. pylori* purified LPS could inhibit the binding of laminin to *H. pylori*. Laminin binding was inhibited by homologous and also heterologous smooth-form LPS. Interestingly, nonhemagglutinating strains bind laminin with a higher affinity (K_d = 4.1 pM) than do hemagglutinating strains (K_d = 8.5 pM) but more binding sites are available on the surface of hemagglutinating strains, thereby explaining the higher extent of laminin binding by these strains (104). Thus, the hydrophobic surface-exposed component responsible for laminin binding previously described by Trust et al. (101) was shown to be attributable in part to LPS. The ability of heterologous rough LPS to produce

FIG. 2. *H. pylori* invasion model stressing the potential role of plasminogen-binding protein in facilitating movement through the gastric epithelium. Plasmin has the potential to degrade ECM protein and could permit migration of the bacteria into tissue. Cell-bound plasminogen is activated to plasmin and can no longer be inhibited by α2-antiplasmin.

inhibition comparable to that caused by smooth LPS indicated that the O side chain was not involved in the interaction. In fact, using dephosphorylated LPS, isolated core oligosaccharides, and free lipid A in inhibitory experiments for the studied hemagglutinating and poorly hemagglutinating strains, a phosphorylated structure and a conserved nonphosphorylated structure in the core oligosaccharide mediated the interaction, respectively. Scatchard plot analysis of data for the laminin binding by LPS indicated the presence of a single class of binding molecules with a dissociation constant of 2.5 nM. The authors postulated that the initial recognition and binding of laminin by *H. pylori* could occur through LPS and that subsequently a more specific interaction involving a lectin-like protein present on the bacterial cell surface could take place.

Slomiany et al. (90) demonstrated that *H. pylori* cells, in particular *H. pylori* LPS, inhibited the interaction between a laminin receptor in gastric epithelial cells and laminin. They isolated from rat gastric epithelial cell membranes a protein of 67 kDa that was shown to bind laminin. This protein receptor incorporated in liposomes displayed specific binding toward laminin, and the reaction was inhibited by LPS from *H. pylori*. A similar process may account for the loss of mucosal integrity in the pathogenesis of *H. pylori*-associated gastric disease. The subsequent disruption of epithelial cell- basement membrane interaction by LPS would explain the development and gradual loss of mucosal integrity during *H. pylori* infection (68).

A laminin-binding protein was identified on *H. pylori* (106). Inhibition of laminin binding by fetuin, but not asialofetuin, and reduced bacterial binding to periodate- or sialidase-treated laminin confirmed earlier results indicating that glycosylation and particularly sialylation were important for laminin binding by *H. pylori*. In fact, by using mono, di, and trisaccharides in inhibition experiments, it was shown that *H. pylori* bound to a region spanning a trisaccharide, in particular the trisaccharide *N*-acetylneuraminyl-(alpha-2-3)-lactose. Although LPS is involved in binding to laminin, inhibition experiments and heat and protease treatment of *H. pylori* cells indicated that a protein receptor, rather than LPS, on *H. pylori* bound this trisaccharide. Using Western blotting, a 25-kDa

outer membrane protein was identified as responsible for the laminin-binding activity by both hemagglutinating and poorly hemagglutinating strains. Thus, it appears that this 25-kDa outer membrane protein acts as a lectin-like molecule together with *H. pylori* LPS to mediate attachment to laminin.

As stated above, the lectin-binding activity to laminin may disrupt epithelial cell-basement membrane interactions and may be responsible for the epithelial leakiness typically observed in *H. pylori* infections. The capacity of *H. pylori* to rapidly, avidly, and largely irreversibly bind both type IV collagen and laminin should facilitate both initial and continued colonization of any basement membrane that becomes exposed as a result of either *H. pylori*-induced disruption of mucosal integrity or the loss of epithelial cells resulting from eating and drinking, for example. Furthermore, the capacity to bind those proteins at both acidic and alkaline pH should promote the continued colonization of any ulcerative lesions formed in either the acidic stomach or the alkaline duodenum. Laminin binding may enable the pathogen to survive in chronically inflamed tissue.

Plasminogen and Plasmin

Plasminogen is a plasma and ECM glycoprotein composed of a 90-kDa single chain proenzyme in its native form. It is the main component of the fibrinolytic system (112) and circulates in plasma as an inactive zymogen, which under certain conditions is activated, by proteolytic cleavage, to the active form, plasmin (a serine protease). Activators such as urokinase and tissue type plasminogen activator convert plasminogen to plasmin. Plasminogen is a component of the fibrinolytic system, which is present in the plasma, subepithelial, and subendothelial basement membranes. It can be converted to a serine proteinase by a number of activators of eukaryotic and bacterial origin (44). The main function of plasminogen is to mediate fibrinolysis in normal hemostasis, a process in which fibrin is degraded to fibrin fragments. Plasmin is a potent enzyme that can dissolve blood clots. In addition, it can directly hydrolyze matrix proteins such as laminin, fibronectin, and collagens.

Plasminogen receptors are present on leukocytes, platelets, and the cell surface of several bacterial pathogens (50). Cell surface-bound plasminogen is easily activated to plasmin. Binding and activation of human plasminogen on the surface of bacterial cells is a common mechanism used by certain invasive bacteria to facilitate movement through normal tissue barriers (50). This provides the bacterium with a potent serine protease that has a broad enzyme specificity and may contribute to tissue breakdown, facilitating the invasion of *H. pylori* through the gastric epithelium as well as providing nutrients. It could enable bacterial pathogens to utilize the ECM proteins to penetrate infected tissue and be disseminated. In fact, degradation of matrix proteins is required to facilitate the movement of cells through tissue planes in various biological processes such as wound repair, tissue remodeling, and tumor cell metastasis (84). Bacteria able to acquire the host's enzymes with broad substrate specificity could dramatically alter the dynamics of the host-microbe relationship to favor the establishment of a long-lasting infection.

H. pylori binds to plasminogen, and the interaction is not sialic acid dependent (83). Radiolabeled plasminogen binds to hemagglutinating *H. pylori* strain 17874 at a high level (32%). The interaction is specific since it could not be inhibited by nonlabeled plasminogen. This interaction seems to be a common phenomenon among *H. pylori* strains (47). Plasminogen binding to *H. pylori* seems to be independent of the presence of CagA (75). The inhibition of binding by lysine and lysine analogues indicates that lysine residues are important for binding to plasminogen. It was suggested that *H. pylori* binds the fifth kringle structure of the plasminogen molecule. Two proteins (of 42 and 57 kDa) binding to plasminogen were identified by Pantzar et al. (75). Scatchard plot analysis revealed a unique molecule binding plasminogen with a dissociation constant of 7×10^{-7} M. No significant difference was found between binding to the spiral and the coccoid form of *H. pylori* (39). Conversion of *H. pylori* cell-bound plasminogen to plasmin in the presence of a tissue type plasminogen activator was demonstrated in vitro (Fig. 2). At the same time, receptor-bound plasmin is protected from inactivation by α_2-antiplasmin. In essence, plasminogen receptors and activators turn bacteria into proteolytic organisms using a host-derived system. For *H. pylori,* binding is pH dependent with an optimum at pH 7. Although *H. pylori* survives the obligatory passage through the low pH in gastric juice, it prefers an environment close to the epithelial surface, embedded in mucus, where the pH is higher, this may account for the optimum pH observed. No activation was noted when plasminogen or tissue- type plasminogen activator was incubated with *H. pylori* cells alone. This indicates that *H. pylori* requires a host activator since it does not produce its own bacterial plasminogen activator. By using a different approach, Yarzábal et al. (112) identified a 58.9-kDa plasminogen-binding protein in a water extract of surface protein. The identified protein had a molecular mass similar to those of the proteins found in another strain of *H. pylori* (75).

However, a recent study demonstrated that *H. pylori* NAP could increase the production of tissue factor and of plasminogen activator inhibitor type 2 but not of urokinase type plasminogen activator by human blood mononuclear cells (66). Clotting assays established that NAP-induced tissue factor is functionally active, thus triggering blood-clotting activation and promoting fibrin formation. The up-regulation of plasminogen activator inhibitor type 2 results in impaired proteolysis in the cell environment. Thus, NAP, by inducing the coordinate expression of cell procoagulant and antifibrinolytic activities, could favor fibrin deposition and contribute to the inflammatory reaction of the gastric mucosa elicited by *H. pylori.*

The plasminogen binding and conversion to plasmin is the only known proteolytic activity of *H. pylori* (69). This proteolytic activity may enhance tissue penetration and be involved in carcinogenesis. For now, in vivo evidence for a role of plasminogen activation in pathogenesis is limited to *Yersinia pestis, Borrelia,* and group A streptococci (44). Experiments with *H. pylori* should now be conducted in animal models to evaluate the role of plasminogen binding in the pathogenesis.

Vitronectin

Vitronectin (also called serum-spreading factor or S-protein) is a serum and ECM glycoprotein known to promote the attachment and spreading of cells in vitro. It also interacts with the C5b-9 complex inhibiting cell lysis by the complement system and protects thrombin from inactivation by antithrombin III. Vitronectin binds to *H. pylori* (53%) (82, 83), and this reaction is fast, saturable, and reversible. Binding is heat and protease sensitive, suggesting that it is mediated by bacterial cell surface proteins. Cell surface protein extracts partly inhibited the binding, indicating that the vitronectin- binding structures are easily extracted surface proteins. Sialic acid-specific hemagglutinins were suspected to mediate this reaction since the reaction was inhibited by fetuin and orosomucoid but not by asialofetuin. Low (5 to 8%) and high (>50%) vitronectin binders were observed among hemagglutinating strains. Purified vitronectin, which includes an urea-activation step of vitronectin, binds to *H. pylori* in a fast and saturable way (82). On the other hand, Trust et al. (101) reported that only small amounts of vitronectin, purified by another method, bound to *H. pylori.* This discrepancy could be explained by the fact that vitronectin exists in at least two structurally and functionally distinct forms in human plasma.

Binding of vitronectin, type IV collagen, and laminin, all ECM molecules, may be important for *H. pylori* to protect itself from cell lysis by complement or from other immunological effects. Ringnér et al. (83) also showed a specific, saturable, and dose- dependent binding of ^{125}I-vitronectin to hemagglutinating *H. pylori* strain 17874. The reaction was pH dependent, and maximal binding was attained at pH 4. Growth conditions influenced the expression of vitronectin-binding properties, since *H. pylori* grown on agar bound 50% more vitronectin than did broth-cultured bacteria. Competition experiments using ^{125}I-labeled vitronectin and plasminogen indicated that the binding sites for those molecules were different. However, they are probably close together, since nonlabeled vitronectin could inhibit the binding of ^{125}I-plasminogen but nonlabeled plasminogen had no effect on ^{125}I-vitronectin binding.

Although vitronectin treatment of *H. pylori* slightly reduced the uptake of bacteria by macrophages, the simultaneous treatment with vitronectin and complement rendered them resistant to phagocytosis (14). Whether the cell surface-bound plasmin is of any importance in the development of gastric cancer by *H. pylori* remains to be investigated.

Mucus Loosening

1 *H.pylori*

Acid Permeation

NAP

2

CagA

3 VacA

4

$Mucus\ Layer$

$Epithelium$

Alteration of the Gastric Mucosa (Peptic Ulcers ?)

Degradation of ECM Proteins

Exposure of ECM and Leakage of Serum Proteins

Tissue Erosion

+ Host Plasminogen Activator

Plasmin (serine protease)

11

Interaction with Growth Factors and Growth Factor Receptors

$Lamina\ Propria$

Blood Vessel

Way to evade Host Immunological defenses ⟵ IgG Binding

Mimicry stratagem ⟵ Albumin Binding

Plasminogen

5

6

Heparan Sulfate/Heparin

7

Fibronectin/Fibrinogen

9

Laminin

8

Vitronectin

Long-lasting Infection

Colonization of Ulcerative Lesions

Protection from Cell Lysis by Complement or other Immunological Effects

Collagens

10

Affect Mucosal Integrity by Interfering with the Laminin-Laminin Receptor Interaction

Lamina Propria Invasion

FIG. 3. Schematic representation of the binding events that could take place between *H. pylori* and certain host serum and ECM proteins and the inferred resulting effects on the infectious process. Once the bacterium has entered the gastric lumen, its flagella propel it into the mucus layer (step 1) and allow it to reach the apex of the gastric epithelial cells, to which it sticks via specialized adhesins (step 2). *H. pylori* can, using a type IV secretion system, inject CagA protein into the host cells and also release other toxic factors such as NAP and VacA. Alterations of the tight junctions and formation of large vacuoles result from VacA action. Toxic activity of VacA and of reactive oxygen intermediates produced as a result of NAP leads to a loss of integrity of the epithelial mucosal surface, by exposing molecules constituting the ECM as well as leaking of serum proteins (step 3). Tissue damage is enhanced due to loosening of the protective mucus layer and acid permeation (step 4). As in vitro studies have shown, plasminogen, after binding to the *H. pylori* cell surface, could, in the presence of host plasminogen activator, be transformed into plasmin (a serine protease) that could be directly involved in the degradation of various ECM proteins (including fibronectin, fibrinogen, laminin, and collagens). This host-derived proteolytic activity could be involved directly in tissue erosion (step 5). *H. pylori* could bind heparan sulfate (and probably heparin after release from intracellular granules) and interfere with growth factors and growth factor receptors affecting the gastric mucosa. This interaction could be involved in peptic ulcer production (step 6). The bacterium could also bind weakly to fibronectin and fibrinogen molecules and permit the establishment of a long-lasting infection (step 7). Binding to vitronectin could result in protection from complement cell lysis or other immunological effects (step 8). Laminin- binding could promote continuous colonization of basement membrane and of ulcerative lesions. It could also account for the loss of mucosal integrity observed in *H. pylori* infection by interfering with the reaction between the laminin receptor and laminin that accounts for the basement membrane structure (step 9). In ulcerated tissue, collagen molecules become exposed and are available to *H. pylori*, probably helping invasion of the lamina propria (step 10). Tissue alteration and ulceration could also lead to leakage of serum proteins following blood vessel disruption. Binding to immunoglobulins could provide the pathogen with a way to evade the host immunological defenses by interfering with opsonization, phagocytosis, and/or complement activation and comsumption. Albumin coating could also provide a mimicry stratagem so the invader is recognized as self (step 11). Taken together, those numerous reactions with host proteins would permit the establishment of a long-lasting infection, as observed for *H. pylori*.

CONCLUDING REMARKS

The study of bacterial interactions with serum and ECM proteins aims first at understanding the infection process and the settling of a long-lasting infection and second at establishing therapy methods based on preventing receptin binding and on attempts to prevent deeper tissue invasive infections. With the increasing prevalence of antibiotic-resistant strains, this new approach could provide alternatives to antibiotic treatment. This path could also be considered a complementary or alternative treatment of peptic ulcer induced by *H. pylori*. Before any antibacterial surface-coating strategy can be optimized for application in body compartments, the receptin-binding mechanisms will have to be elucidated in detail. As stated above, the receptins would act in conjunction with the virulence (toxic) factors described for *H. pylori* and would help establish this frequently observed lifelong infection.

For certain microorganisms, receptins binding to host proteins have recently been shown to contribute to virulence in animal models. For example, a fibrinogen-binding protein of *Streptococcus equi* subsp. *equi* was protective against a lethal challenge in mice (59). This protein was shown to bind equine fibrinogen as well as IgG and to contribute to virulence in a mouse model, since a knockout mutant, which did not express fibronectin-binding protein on the cell surface, showed a greatly decreased virulence (58). In addition, the molecule had antiphagocytic properties that could account for the virulence of *S. equi* subsp. *equi*. For *Mycobacterium tuberculosis,* a heparin-binding haemagglutinin adhesin markedly affected interactions of the bacteria with epithelial cells but not with macrophage-like cells (79). When administered intranasally to mice, a strain mutated for the heparin-binding protein was severely impaired in spleen colonization but not in lung colonization. Coating of wild-type mycobacteria with antibodies directed against the heparin-binding protein also prevented dissemination after intranasal infection. Thus, it appears that such a heparin- binding hemagglutinin is required for extrapulmonary dissemination of the microorganism, as revealed in the mouse model. Concerning *H. pylori,* it was observed that intragastric vaccination with heparan sulfate-binding protein covalently coupled to the beta-subunit of cholera toxin protected mice against a challenge with *H. pylori,* as revealed by microbiological, histopathological, and molecular methods (87).

The numerous receptins described for *H. pylori* should not be surprising since this bacterium, in order to be a long-term resident in the human host, must have the potential to express many binding molecules at different times during the infectious process and in different combinations (Fig. 3). As we have observed for this pathogen, the interactions with certain host proteins are of high affinity and therefore are most probably not negligible as a pathogenicity attribute. The multiplicity of both receptins and their respective binding molecules (ligands) allows the bacteria to survive in a very dynamic microenvironment as the infection evolves, in some instances, to an invasive stage. These adherence-penetration phenomena involve coating of the microbe with host proteins to escape the host immune system and initiate a chronic lifelong infection process.

Vaccines based on recombinant ECM-binding proteins were shown for *S. aureus,* for example, to be much more protective than those based on whole bacteria (31). Binding of large amounts of a soluble host protein to the bacterial surface may result in a protective coat, allowing the bacteria to evade recognition by host defense mechanisms. An advantage for the microorganism would be the ability to up-regulate the expression of receptins when it senses attachment to serum or ECM molecules, allowing more effective colonization, invasion, and destruction of host tissues. Thus, a study of the environmental control of bacterial receptins should be pursued in order to better understand the signal(s) triggering the regulation of receptins elaborated by *H. pylori*. Potential targets for the development of novel strategies against *H. pylori* could include subunit vaccines as well as receptin blockers. Although the pieces of the puzzle are not all in place yet, we can recognize the potential importance of binding to host proteins by pathogenic microorganisms like *H. pylori* during the infectious process.

REFERENCES

1. **Alm, R. A., L.-S. L. Ling, D. T. Moir, B. L. King, E. D. Brown, P. C. Doig, D. R. Smith, B. Noonan, B. C. Guild, B. L. deJonge, G. Carmel, P. J. Tummino, A. Caruso, M. Uria-Nickelsen, D. M. Mills, C. Iyes, R. Gibson, D. Merberg, S. D. Mills, Q. Jiang, D. E. Taylor, G. F. Vovis, and T. J. Trust.** 1999. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen *Helicobacter pylori.* Nature **397:**176–180.
2. **Amini, H.-R., F. Ascencio, A. Cruz-Villacorta, E. Ruiz-Bustos, and T. Wadström.** 1996. Immunochemical properties of a 60 kDa cell surface- associated heat shock-protein (Hsp60) from *Helicobacter pylori.* FEMS Immunol. Med. Microbiol. **16:**163–172.
3. **Amini, H.-R., F. Ascencio, A. Ljungh, and T. Wadström.** 1995. Particle agglutination assay for detection of albumin and IgG binding cell surface components of *Helicobacter pylori.* Zentbl. Bacteriol. Mikrobiol. Hyg. **282:** 255–264.
4. **Appelmelk, B. J., I. Simoons-Smit, R. Negrini, A. P. Moran, G. O. Aspinall, J. G. Forte, T. De Vries, H. Quan, T. Verboom, J. J. Maaskant, P. Ghiara, E. J. Kuipers, E. Bloemena, T. M. Tadema, R. R. Townsend, K. Tyagarajan, J. M. Jr. Crothers, M. A. Monteiro, A. Savio, and J. De Graaff.** 1996. Potential role of molecular mimicry between *Helicobacter pylori* lipopolysaccharide and host Lewis blood group antigen in autoimmunity. Infect. Immun. **64:**2031–2040.
5. **Ascencio, F., L. A. Fransson, and T. Wadström.** 1993. Affinity of the gastric pathogen *Helicobacter pylori* for the N-sulphated glycosaminoglycan heparan sulphate. J. Med. Microbiol. **38:**240–244.
6. **Ascencio, F., L. A. Hansson, O. Larm, and T. Wadström.** 1995. *Helicobacter pylori* interacts with heparin and heparin-dependent growth factors. FEMS Immunol. Med. Microbiol. **12:**265–272.
7. **Berstad, A. E., K. Holbjorn, G. Bukholm, A. P. Moran, and P. Brandtzaeg.** 2001. Complement activation directly induced by *Helicobacter pylori.* Gastroenterology **120:**1108–1116.
8. **Berstad, A. E., M. Kilian, K. N. Valnes, and P. Brandtzaeg.** 1999. Increased mucosal production of monomeric IgA$_1$ but not IgA$_2$ protease activity in *Helicobacter pylori* gastritis. Am. J. Pathol. **155:**1097–1104.
9. **Bode, G., P. Malfertheiner, and H. Ditschuneit.** 1988. Pathogenic implications of ultrastructural findings in *Campylobacter pylori* related gastroduodenal disease. Scand. J. Gastroenterol. **142:**25–39.
10. **Boren, T., P. Falk, K. A. Roth, G. Larson, and S. Normark.** 1993. Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. Science **262:**1892–1895.
11. **Boyle, M. D. P. (ed.).** 1990. Bacterial immunoglobulin binding proteins, vol. 1. Academic Press, Inc., San Diego, Calif.
12. **Buck, G. E., W. K. Gourley, W. K. Lee, K. Subramanyam, J. M. Latimer, and A. R. DiNuzzo.** 1986. Relationship of *Campylobacter pyloridis* to gastritis and peptic ulcer. J. Infect. Dis. **153:**664–669.
13. **Censini, S., C. Lange, Z. Xiang, J. E. Crabtree, P. Ghiara, M. Borodovsky, R. Rappuoli, and A. Covacci.** 1996. cag, a pathogenecity island of *Helicobacter pylori,* encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. USA **93:**14648–14653.
14. **Chmiela, M., E. Czkwianianc, T. Wadström, and W. Rudnicka.** 1997. Role of *Helicobacter pylori* surface structures in bacterial interaction with macrophages. Gut **40:**20–24.

15. **Chmiela, M., J. Lelwala-Guruge, and T. Wadström.** 1994. Interaction of cells of *Helicobacter pylori* with human polymorphonuclear leukocytes: possible role of haemagglutinins. FEMS Immunol. Med. Microbiol. **9:**41–48.

16. **Chmiela, M., B. Paziak-Domanska, W. Rudnicka, and T. Wadström.** 1995. The role of heparan sulphate-binding activity of *Helicobacter pylori* bacteria in their adhesion to murine macrophages APMIS **103:**469–474.

17. **Chmiela, M., B. Paziak-Domanska, and T. Wadström.** 1995. Attachment, ingestion and intracellular killing of *Helicobacter pylori* by human peripheral blood mononuclear leukocytes and mouse peritoneal inflammatory macrophages. FEMS Immunol. Med. Microbiol. **10:**307–316.

18. **Covacci, A., and R. Rappuoli.** 2000. Tyrosine-phosphorylated bacterial proteins: trojan horses for the host cell. J. Exp. Med. **191:**587–592.

19. **Covacci, A., S. Censini, M. Bugnoli, R. Petracca, D. Burroni, G. Macchia, A. Massone, E. Papini, Z. Xiang, N. Figura, and R. Rappuoli.** 1993. Molecular characterization of the 128-kDa immunodominant antigen of *Helicobacter pylori* associated with cytotoxicity and duodenal ulcer. Proc. Natl. Acad. Sci. USA **90:**5791–5795.

20. **Cover, T. L., and M. J. Blaser.** 1992. Purification and characterization of the vacuolating toxin from *Helicobacter pylori.* J. Biol. Chem. **267:**10570–10575.

21. **De Bernard, M., B. Arico, E. Papini, R. Rizzuto, G. Grandi, R. Rappuoli, and C. Montecucco.** 1997. *Helicobacter pylori* toxin VacA induces vacuole formation by acting in the cell cytosol. Mol. Microbiol. **26:**665–674.

22. **Del Giudice, G., A. Covacci, J. L. Telford, C. Montecucco and R. Rappuoli.** 2001. The design of vaccines against *Helicobacter pylori* and their development. Annu. Rev. Immunol. **19:**523–563.

23. **Deltenre, M., and E. de Koster.** 2000. How come I've got it? (A review of *Helicobacter pylori* transmission). Eur. J. Gastroenterol. Hepatol. **12:**479–482.

24. **Duensing, T. D., J. S. Wing, and J. P. M van Putten.** 1999. Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect. Immun. **67:**4463–4468.

25. **Dunn, B. E., H. Cohen, and M. J. Blaser.** 1997. *Helicobacter pylori.* Clin. Microbiol. Rev. **10:**720–741.

26. **Eaton, K. A., and M. E. Mefford.** 2001. Cure of *Helicobacter pylori* infection and resolution of gastritis by adoptive transfer of splenocytes in mice. Infect. Immun. **69:**1025–1031.

27. **Evans, D. J., Jr., D. G. Evans, T. Takemura, H. Nakano, H. C. Lampert, D. Y. Graham, D. N. Granger, and P. R. Kvietys.** 1995. Characterization of a *Helicobacter pylori* neutrophil-activating protein. Infect. Immun. **63:**2213–2220.

28. **Evans, D. G., D. J. Jr. Evans, Jr., J. J. Moulds, and D. Y. Graham.** 1988. *N*-Acetyl-neuraminyllactose-binding fibrillar hemagglutinin of *Campylobacter pylori:* a putative colonization factor antigen. Infect. Immun. **56:**2896–2906.

29. **Everhart, J. E.** 2000. Recent developments in the epidemiology of *Helicobacter pylori.* Gastroenterol. Clin. North Am. **29:**559–578.

30. **Ferrero, R. L., J. M. Thiberge, I. Kansau, N. Wuscher, M. Huerre, and A. Labigne.** 1995. The GroES homolog of *Helicobacter pylori* confers protective immunity against mucosal infection in mice. Proc. Natl. Acad. Sci. USA **92:**6499–6503.

31. **Flock, J.-I.** 1999. Extracellular-matrix-binding proteins as targets for the prevention of *Staphylococcus aureus* infections. Mol. Med. Today **5:**532–537.

32. **Gonzalez-Valencia, G., G. I. Perez-Perez, R. G. Washburn, and M. J. Blaser.** 1996. Susceptibility of *Helicobacter pylori* to the bactericidal activity of human serum. Helicobacter **1:**28–33.

33. **Gotoda, T., D. Saito, H. Kondo, H. Ono, I. Oda, M. Fujishiro, and H. Yamaguchi.** 1999. Endoscopic and histological reversibility of gastric adenoma after eradication of *Helicobacter pylori.* J. Gastroenterol. **34:**91–96.

34. **Guzman-Murillo, M. A., E. Ruiz-Bustos, B. Ho, and F. Ascencio.** 2001. Involvement of the heparan sulphate-binding proteins of *Helicobacter pylori* in its adherence to HeLa S3 and Kato III cell lines. J. Med. Microbiol. **50:**320–329.

35. **Hancock, R. E. W., R. Alm, J. Bina, and T. J. Trust.** 1998. The complete genome sequence of the gastric pathogen *Helicobacter pylori:* a surprisingly conserved bacterium. Nat. Biotechnol. **16:**216–217.

36. **Hirmo, S., M. Utt, M. Ringnér, and T. Wadström.** 1995. Inhibition of heparan sulphate and other glycosaminoglycans binding to *Helicobacter pylori* by various polysulphated carbohydrayes. FEMS Immunol. Med. Microbiol. **10:**301–306.

37. **Hoepelman, A. I., and E. I. Tuomanen.** 1992. Consequences of microbial attachment: direct host cell function with adhesins. Infect. Immun. **60:**1729–1733.

38. **Hu, L.-T., and H. L. T. Mobley.** 1990. Purification and N-terminal analysis of urease from *Helicobacter pylori.* Infect. Immun. **58:**992–998.

39. **Khin, M. M., M. Ringnér, P. Aleljung, T. Wadström, and B. Ho.** 1996. Binding of human plasminogen and lactoferrin by *Helicobacter pylori* coccoid forms. J. Med. Microbiol. **45:**433–439.

40. **Kostrzynska, M., J. D. Betts, J. W. Austin, and T. J. Trust.** 1991. Identification, characterization, and spatial localization of two flagellin species in *Helicobacter pylori* flagella. J. Bacteriol. **173:**937–946.

41. **Kronvall, G., and K. Jönsson.** 1999. Receptins: a novel term for an expanding spectrum of natural and engineered microbial proteins with binding properties for mammalian proteins. J. Mol. Recognit. **12:**38–44.

42. **Kuusela, P.** 1978. Fibronectin binds to *Staphylococcus aureus.* Nature **276:** 718–720.

43. **Kwok, T., S. Backert, H. Schwarz, J. Berger and T. F. Meyer.** 2002. Specific entry of *Helicobacter pylori* into cultured gastric epithelial cells via a zipper-like mechanism. Infect. Immun. **70:**2108–2120.

44. **Lähteenmaki, K., P. Kuusela, and T. M. Korhonen.** 2001. Bacterial plasminogen activators and receptors. FEMS Microbiol. Rev. **25:**531–552.

45. **Lelwala-Guruge, J., C. Schalén, I. Nilsson, A. Ljungh, T. Tyszkiewicz, M. Wikander, and T. Wadström.** 1990. Detection of antibodies to *Helicobacter pylori* cell surface antigens. Scand. J. Infect. Dis. **22:**457–465.

46. **Ljubicic, N., M. Banic, M. Kujundzic, Z. Antic, M. Vrkljan, I. Kovacevic, D. Hrabar, M. Doko, M. Zovak, and S. Mihatov.** 1999. The effect of eradicating *Helicobacter pylori* infection on the course of adenomatous and hyperplastic gastric polyps. Eur. J. Gastrenterol. Hepatol. **11:**727–730.

47. **Ljungh, A.** 2000. *Helicobacter pylori* interactions with plasminogen. Methods **21:**151–157.

48. **Ljungh, A., A. P. Moran, and T. Wadström.** 1996. Interactions of bacterial adhesins with extracellular matrix and plasma proteins: pathogenic implications and therapeutic possibilities. FEMS Immunol. Med. Microbiol. **16:**117–126.

49. **Ljungh, A., and T. Wadström.** 1996. Interaction of bacterial adhesins with the extracellular matrix. Adv. Exp. Med. Biol. **408:**129–140.

50. **Lottenberg, R., D. Minning-Wenz, and M. D. P. Boyle.** 1994. Capturing host plasmin(ogen): a common mechanism for invasive pathogens? Trends Microbiol. **2:**20–24.

51. **Macchia, G., A. Massone, D. Burroni, A. Covacci, S. Censini, and R. Rappuoli.** 1993. The Hsp60 protein of *Helicobacter pylori:* structure and immune response in patients with gastroduodenal diseases. Mol. Microbiol. **9:**645–652.

52. **Malaty, H. M., T. Kumagai, E. Tanaka, H. Ota, K. Kiyosawa, D. Y. Graham, and T. Katsuyama.** 2000. Evidence from a nine-year birth cohort study in Japan of transmission pathways of *Helicobacter pylori* infection. J. Clin. Microbiol. **38:**1971–1973.

53. **Marcus, E. A., and D. R. Scott.** 2001. Cell lysis is responsible for the appearance of extracellular urease in *Helicobacter pylori.* Helicobacter **6:**93–99.

54. **Marshall, B. J.** 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet **1:**1273–1275.

55. **Masuda, Y., and T. Sugiyama.** 2001. A protein in the cell wall of *Helicobacter pylori* binds human IgG deprived of sugar chains. Tohoku J. Exp. Med. **194:**65–69.

56. **Mattsson, A., M. Quiding-Jarbrink, H. Lonroth, A. Hamlet, I. Ahlstedt, and A. Svennerholm.** 1998. Antibody-secreting cells in the stomachs of symptomatic and asymptomatic *Helicobacter pylori*-infected subjects. Infect. Immun. **66:**2705–2712.

57. **McNulty, C. A.** 1999. The discovery of *Campylobacter*-like organisms. Curr. Top. Microbiol. Immunol. **241:**1–9.

58. **Meehan, M., Y. Lynagh, C. Woods, and P. Owen.** 2001. The fibrinogen-binding protein (FgBP) of *Streptococcus equi* subsp. *equi* additionally binds IgG and contributes to virulence in a mouse model. Microbiology **147:**3311–3322.

59. **Meehan, M., P. Nowlan, and P. Owen.** 1998. Affinity purification and characterization of a fibrinogen-binding protein complex which protects mice against lethal challenge with *Streptococcus equi* subsp. *equi.* Microbiology **144:**993–1003.

60. **Mentis, A., L. Tzouvelekis, C. Spiliadis, C. C. Blackwell, and D. M. Weir.** 1990. Inhibition of *Helicobacter pylori* haemagglutination activity by human salivary mucins. FEMS Microbiol. Immunol. **2:**125–127.

61. **Meucci, G., M. Tatarella, M. Vecchi, M. L. Ranzi, E. Biguzzi, G. Beccari, E. Clerici, and R. de Franchis.** 1997. High prevalence of *Helicobacter pylori* infection in patients with colonic adenomas and carcinomas. J. Clin. Gastroenterol. **25:**605–607.

62. **Miehlke, S., R. Thomas, O. Gutierrez, D. Y. Graham, and M. F. Go.** 1999. DNA fingerprinting of single colonies of *Helicobacter pylori* from gastric cancer patients suggests infection with a single predominant strain. J. Clin. Microbiol. **37:**245–247.

63. **Mobley, H. L., R. M. Garner, and P. Bauerfeind.** 1995. *Helicobacter pylori* nickel-transport gene *nixA:* synthesis of catalytically active urease in *Escherichia coli* independent of growth conditions. Mol. Microbiol. **1:**97–109.

64. **Montecucco, C., E. Papini, M. de Bernard, and M. Zoratti.** 1999. Molecular and cellular activities of *Helicobacter pylori* pathogenic factors. FEBS Lett. **452:**16–21.

65. **Montecucco, C., and R. Rappuoli.** 2001. Living dangerously: How *Helicobacter pylori* survives in the human stomach. Nat. Rev. **2:**457–466.

66. **Montemurro, P., G. Barbuti, W. G. Dundon., G. Del Giudice, R. Rappuoli, M. Colucci, P. De Rinaldis, C. Montecucco, N. Semeraro, and E. Papini.** 2001. *Helicobacter pylori* neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells. J. Infect. Dis. **183:**1055–1062.

67. **Montemurro, P., H. Nishioka, W. G. Dundon, M. de Bernard, G. Del**

Giudice, R. Rappuoli, and C. Montecucco. 2002. The neutrophil-activating protein (HP-NAP) of *Helicobacter pylori* is a potent stimulant of mast cells. Eur. J. Immunol. **32:**671–676.

68. Moran, A. P., P. Kuusela, and T. U. Kosunen. 1993. Interaction of *Helicobacter pylori* with extracellular matrix proteins. J. Appl. Bacteriol. **75:**184–189.

69. Nilius, M., M. Pugliese and P. Malfertheiner. 1996. *Helicobacter pylori* and proteolytic activity. Eur. J. Clin. Investig. **26:**1103–1106.

70. Oderda, G. 1999. Transmission of *Helicobacter pylori* infection. Can. J. Gastroenterol. **13:**595–597.

71. Odenbreit, S., B. Wieland, and R. Haas. 1996. Cloning and genetic characterization of *Helicobacter pylori* catalase and construction of a catalase-deficient mutant strain. J. Bacteriol. **178:**6960–6967.

72. Ottemann, K. M., and A. C. Lowenthal. 2002. *Helicobacter pylori* uses motility for initial colonization and to attain robust infection. Infect. Immun. **70:**1984–1990.

73. O'Toole, P. W., M. C. Lane, and S. Porwollik. 2000. *Helicobacter pylori* motility. Microbes Infect. **2:**1207–1214.

74. Pakodi, F., O. M. Abdel-Salam, A. Debreceni, and G. Mozsik. 2000. *Helicobacter pylori:* one bacterium and a broad spectrum of human disease An overview. J. Physiol. (Paris) **94:**139–152.

75. Pantzar, M., A. Ljungh, and T. Wadström. 1998. Pasminogen binding and activation at the surface of *Helicobacter pylori* CCUG 17874. Infect. Immun. **66:**4976–4980.

76. Patti, J. M., B. L. Allen, M. J. McGavin, and M. Höök. 1994. MSCRAMM-Mediated adherence of microorganisms to host tissues. Annu. Rev. Microbiol. **48:**585–617.

77. Patti, J. M., and M. Höök. 1994. Microbial adhesins recognizing extracellular matrix macromolecules. Curr. Opin. Cell Biol. **6:**752–758.

78. Peters, T., Jr. 1996. All about albumin: biochemistry, genetics, and medical applications, Academic Press, Inc., New York, NY.

79. Pethe, K., S. Alonso, F. Biet, G. Delogu, M. J. Brennan, C. Locht, and F. D. Menozzi. 2001. The heparin-binding haemagglutinin of *M. tuberculosis* is required for extrapulmonary dissemination. Nature **412:**190–194.

80. Polla, B. S., S. Baladi, K. Fuller, and G. Rook. 1995. Presence of hsp65 in bacterial extracts (OM-89): a possible mediator of orally induced tolerance? Experientia **51:**775–779.

81. Reyrat, J. M., S. Lanzavecchia, P. Lupetti, M. de Bernard, C. Pagliaccia, V. Pelicic, M. Charrel, C. Ulivieri, N. Norais, X. Ji, V. Cabiaux, E. Papini, R. Rappuoli, and J. L. Telford. 1999. 3D imaging of the 58 kDa cell binding subunit of the *Helicobacter pylori* cytoxin. J. Mol. Biol. **290:**459–470.

82. Ringnér, M., M. Paulsson, and T. Wadström. 1992. Vitronectin binding by *Helicobacter pylori*. FEMS Microbiol. Immunol. **5:**219–224.

83. Ringnér, M., K. H. Valkonen, and T. Wadström. 1994. Binding of vitronectin and plasminogen to *Helicobacter pylori*. FEMS Immunol. Med. Microbiol. **9:**29–34.

84. Romer, J., T. H. Bugge, C. Pyke, L. R. Lund, M. J. Flick, J. L. Degen and K. Dano. 1996. Impaired wound healing in mice with a disrupted plasminogen gene. Nat. Med. **2:**287–292.

85. Rothenbacher, D., G. Bode, G. Berg, U. Knayer, T. Gonser, G. Adler, and H. Brenner. 1999. *Helicobacter pylori* among preschool children and their parents: evidence of parent-child transmission. J. Infect. Dis. **179:**398–402.

86. Ruiz-Bustos, E., J. L. Ochoa, T. Wadström, and F. Ascencio. 2001. Isolation and characterization of putative adhesions from *Helicobacter pylori* with affinity for heparan sulphate proteoglycan. J. Med. Microbiol. **50:**215–222.

87. Ruiz-Bustos, E., A. Sierra-Beltran, M. J. Romero, C. Rodriguez-Jaramillo, and F. Ascencio. 2000. Protection of BALB/c mice against experimental *Helicobacter pylori* infection by oral immunisation with *H. pylori* heparan sulphate-binding proteins coupled to cholera toxin beta-subunit. J. Med. Microbiol. **49:**535–541.

88. Satin, B., G. Del Giudice, V. Della Bianca, S. Dusi, C. Laudanna, F. Tonello, D. Kelleher, R. Rappuoli, C. Montecucco, and F. Rossi. 2000. The neutrophil-activating protein (HP-NAP) of *Helicobacter pylori* is a protective antigen and a major virulence factor. J. Exp. Med. **191:**1467–1476.

89. Sjobring, U. 1992. Isolation and molecular characterization of a novel albumin binding protein from group G streptococci. Infect. Immun. **60:**3601–3608.

90. Slomiany, B. L., J. Piotrowski, S. Sengupta, and A. Slomiany. 1991. Inhibition of gastric mucosal laminin receptor by *Helicobacter pylori* lipopolysaccharides. Biochem. Biophys. Res. Commun. **175:**963–970.

91. Smith, V. C., and R. M. Genta. 2000. Role of *Helicobacter pylori* gastritis in gastric atrophy, intestinal metaplasia, and gastric neoplasia. Microsc. Res. Tech. **48:**313–320.

92. Sommi, P., V. Ricci, M. Romano, K. J. Ivey, E. Solcia, and U. Ventura. 1997. *H. pylori*-induced cell vacuolation *in vitro:* inhibitory action of heparin. Gastroenterology **112** (Suppl. S):A294.

93. Spiegelhalder, C., B. Gerstenecker, A. Kersten, E. Schiltz, and M. Kist. 1993. Purification of *Helicobacter pylori* superoxide dismutase and cloning and sequencing of the gene. Infect. Immun. **61:**5315–5325.

94. Supajatura, V., H. Ushio, A. Wada, K. Yahiro, K. Okumura, H. Ogawa, T. Hirayama, and C. Ra. 2002. VacA, a vacuolating cytoxin of *Helicobacter pylori,* directly activates mast cells for migration and production of proinflammatory cytokines. J. Immunol. **168:**2603–2607.

95. Testerman, T. L., D. J. McGee, and H. L. T. Mobley. 2001. Adherence and colonization. p. 381–417. In H. L. T. Mobley, G. L. Mendz, and S. L. Hazell, (ed.), *Helicobacter pylori:* physiology and genetics. ASM Press, Washington, D.C.

96. Thomas, J. E., A. Dale, M. Harding, W. A. Coward, T. J. Cole, and L. T. Weaver. 1999. *Helicobacter pylori* colonization in early life. Pediatr. Res. **45:**218–223.

97. Tindberg, Y., C. Bengtsson, F. Granath, M. Blennow, O. Nyrén, and M. Granström. 2001. *Helicobacter pylori* infection in Swedish school children: Lack of evidence of child-to-child transmission outside the family. Gastroenterology **121:**310–316.

98. Tomb, J.-F., O. White, A. Kerlavage, R. Clayton, G. Sutton, R. Fleischmann, K. Ketchum, H. Klenk, S. Gill, B. Dougherty, K. Nelson, J. Quackenbush, L. Zhou, E. Kirkness, S. Peterson, B. Loftus, D. Richardson, R. Dodson, H. Khalak, A. Glodek, K. McKenney, L. Fitzegerald, N. Lee, M. Adams, E. Hickey, D. Berg, J. Gocayne, T. Utterback, J. Peterson, J. Kelley, M. Cotton, J. Weidman, C. Fujii, C. Bowman, L. Watthey, E. Wallin, W. Hayes, M. Borodovsky, P. Karp, and J. Venter. 1997. The complete genome sequence of the gastric pathogen *Helicobacter pylori*. Nature **388:**539–547.

99. Tombola, F., L. Morbiato, G. Del Giudice, R. Rappuoli, M. Zoratti, and E. Papini. 2001. The *Helicobacter pylori* VacA toxin is a urea permease that promotes urea diffusion across epithelia. J. Clin. Investig. **108:**929–937.

100. Tosi, M. F., and S. J. Czinn. 1990. Opsonic activity of specific human IgG against *Helicobacter pylori*. J. Infect. Dis. **162:**156–162.

101. Trust, T. J., P. Doig, L. Emödy, Z. Kienle, T. Wadström, and P. O'Toole. 1991. High-affinity binding of the basement membrane proteins collagen type IV and laminin to the gastric pathogen *Helicobacter pylori*. Infect. Immun. **59:**4398–4404.

102. Utt, M., B. Danielsson, and T. Wadström. 2001. *Helicobacter pylori* vacuolating cytotoxin binding to a putative cell surface receptor, heparan sulfate, studied by surface plasmon resonance. FEMS Immunol. Med. Microbiol. **30:**109–113.

103. Utt, M., and T. Wadström. 1997. Identification of heparan sulphate binding surface proteins of *Helicobacter pylori:* inhibition of heparan sulphate binding with sulphated carbohydrate polymers. J. Med. Microbiol. **46:**541–546.

104. Valkonen, K. H., M. Ringnér, A. Ljungh, and T. Wadström. 1993. High-affinity binding of laminin by *Helicobacter pylori*. Evidence for a lectin- like interaction. FEMS Immunol. Med. Microbiol. **7:**29–38.

105. Valkonen, K. H., T. Wadström, and A. P. Moran. 1994. Interaction of lipopolysaccharides of *Helicobacter pylori* with basement membrane protein laminin. Infect. Immun. **62:**3640–3648.

106. Valkonen, K. H., T. Wadström, and A. P. Moran. 1997. Identification of the *N*-acetylneuraminyllactose-specific laminin-binding protein of *Helicobacter pylori*. Infect. Immun. **65:**916–923.

107. Wadström, T., S. Hirmo, and T. Boren. 1996. Biochemical aspects of *Helicobacter pylori* colonization of the human gastric mucosa. Aliment. Pharmacol. Ther. Suppl. **1:**17–27.

108. Wadström, T., S. Hirmo, H. Novak, A. Guzman, M. Ringnér- Pantzar, M. Utt, and P. Aleljung. 1997. Sulfatides inhibit binding of *Helicobacter pylori* to the gastric cancer Kato III cell line. Curr. Microbiol. **34:**267–272.

109. Warren, J. R. 1983. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet **i:**1273.

110. Westerlund, B., and T. K. Korhonen. 1993. Bacterial proteins binding to the mammalian extracellular matrix. Mol. Microbiol. **9:**687–694.

111. Widders, P. R. 1990. Fc receptors and the pathogenesis of bacterial infections in animals, p. 375–396. In M. D. P. Boyle (ed.) Bacterial immunoglobulin binding proteins, vol. 1. Academic Press, Inc., San Diego, Calif.

112. Yarzábal, A., L. Avilán, K. Hoelzl, M. de Munoz, J. Puig, and I. Kansau. 2000. A study of the interaction between *Helicobacter pylori* and components of the human fibrinolytic system. Braz. J. Med. Biol. Res. **33:**1015–1021.